Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.11 HKD
16.70 M HKD
1.05 B HKD
192.17 M
About LEES PHARMACEUTICAL HLDGS
Sector
CEO
Wanee Leelalertsuphakun
Headquarters
Hong Kong
Website
Founded
1994
FIGI
BBG000NNJR94
Lee's Pharmaceutical Holdings Ltd. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the Proprietary and Generic Products and Licensed-in Products segments. The Proprietary and Generic Products segment is involved in the manufacturing and sales of self-developed and generic pharmaceutical products. The Licensed-in Products segment focuses on the trading of licensed-in pharmaceutical products. The company was founded by Xiaoyi Li in 1994 and is headquartered in Hong Kong.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 950 is 1.44 HKD — it has increased by 4.35% in the past 24 hours. Watch LEES PHARMACEUTICAL HLDGS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange LEES PHARMACEUTICAL HLDGS stocks are traded under the ticker 950.
950 stock has risen by 2.86% compared to the previous week, the month change is a 19.01% rise, over the last year LEES PHARMACEUTICAL HLDGS has showed a −7.10% decrease.
950 stock is 5.84% volatile and has beta coefficient of 0.46. Track LEES PHARMACEUTICAL HLDGS stock price on the chart and check out the list of the most volatile stocks — is LEES PHARMACEUTICAL HLDGS there?
Today LEES PHARMACEUTICAL HLDGS has the market capitalization of 847.92 M, it has decreased by −0.72% over the last week.
Yes, you can track LEES PHARMACEUTICAL HLDGS financials in yearly and quarterly reports right on TradingView.
LEES PHARMACEUTICAL HLDGS is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
950 net income for the last half-year is 62.48 M HKD, while the previous report showed 581.00 K HKD of net income which accounts for 10.65 K% change. Track more LEES PHARMACEUTICAL HLDGS financial stats to get the full picture.
LEES PHARMACEUTICAL HLDGS dividend yield was 1.18% in 2023, and payout ratio reached 63.38%. The year before the numbers were 1.23% and 22.96% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 25, 2024, the company has 1.06 K employees. See our rating of the largest employees — is LEES PHARMACEUTICAL HLDGS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. LEES PHARMACEUTICAL HLDGS EBITDA is 151.67 M HKD, and current EBITDA margin is 10.43%. See more stats in LEES PHARMACEUTICAL HLDGS financial statements.
Like other stocks, 950 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade LEES PHARMACEUTICAL HLDGS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So LEES PHARMACEUTICAL HLDGS technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating LEES PHARMACEUTICAL HLDGS stock shows the buy signal. See more of LEES PHARMACEUTICAL HLDGS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.